SecBot SecBot
8-K ·Filed Aug 6, 2026

SION

Sionna Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed3mo ago SEC0001628280-26-053832
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor upcoming topline data from the Phase 2a PreciSION CF trial and Phase 1 dual combination trial, expected this summer, these are the primary catalysts for SION. The current cash runway into 2028 provides ample time for data readouts without near-term financing risk.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

SION drug pipeline →

SION-2222

● Neutral Named in this 8-K
Impact
Phase
Phase 2a (scheduled to initiate Q1 2027); Phase 1 completed
Time to market
At least 3 to 5 years away. The dual combination enters Phase 2a in Q1 2027; a successful Phase 2a and subsequent Phase 3 program plus FDA review would be needed before any approval.
Next catalyst
None dated

What to watchThe next catalyst is the initiation of the AscenSION CF Phase 2a proof-of-concept trial for the SION-451 + SION-2222 dual combination, expected in Q1 2027. If the trial starts on schedule, it signals the company is executing on its restructuring plan; a delay would raise concerns given the company's single-asset focus. The actual Phase 2a topline readout is likely 12+ months after initiation and represents the true binary event for the stock.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$49.61
T+0 close · Aug 6, 2026 · via day close
Latest settled
−92.20%
T+60 · $3.87
Vs SPY
−90.53%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $49.61entry
  2. T+1 · 3mo ago +2.88%α +2.27% · $51.04
  3. T+5 · 3mo ago −86.82%α −88.03% · $6.54
  4. T+20 · 3mo ago −86.39%α −86.99% · $6.75
  5. T+60 · 18d ago −92.20%α −90.53% · $3.87
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sionna Therapeutics reported Q2 2026 financial results with a net loss of $29.9M ($-0.66/share), wider than the $18.1M loss in Q2 2025, driven by increased R&D and G&A spending. The filing is a routine quarterly update for a pre-revenue clinical-stage biotech, with no new clinical data or guidance changes, both key pipeline trials remain on track for topline data this summer. Cash burn continues as expected, with $268.3M in cash funding operations into 2028, making this a neutral event with no material surprise vs expectations.

Key Financial Metrics

EPS
−$0.66
est −$0.64 · -3.1%
Rating
in line

Key Facts

  • Net loss of $29.9M for Q2 2026 vs $18.1M in Q2 2025, driven by higher R&D ($21.9M vs $15.4M) and G&A ($10.6M vs $6.5M) expenses.
  • Cash, cash equivalents, and marketable securities totaled $268.3M as of June 30, 2026, expected to fund operations into 2028.
  • PreciSION CF Phase 2a trial of SION-719 and Phase 1 dual combination trial of SION-451 both remain on track for topline data in summer 2026.
  • EPS of $-0.66 for Q2 2026 vs consensus estimate of $-0.64 (a 3.1% miss).
  • No revenue reported; company is a pre-revenue clinical-stage biopharmaceutical company.

Financial Impact

Net loss widened by $11.8M YoY to $29.9M; cash burn of $42M in H1 2026 vs $24M in H1 2025; no revenue

net losscash positionoperating expenses

Risk Factors

  • Phase 2a and Phase 1 trial data may fail to meet efficacy or safety endpoints, which would significantly impair the stock.
  • Widening net losses and increasing cash burn rate could necessitate future dilutive financing if timelines extend beyond current cash runway.
  • Competitive landscape from existing CFTR modulators (e.g., Trikafta) may limit commercial potential even if trials succeed.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-053832
Document: sion-20260806.htm0001628280-26-053832
Document: 0001628280-26-053832-index-headers.html0001628280-26-053832
Document: 0001628280-26-053832-index.html0001628280-26-053832
Document: 0001628280-26-053832.txt0001628280-26-053832
8-K Data (Synthetic)0001628280-26-053832

Track record

22 reports on SION

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +89.29% at T+60 after the Jul 9, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 10, 20266d ago Press Release Neutral 5/10 Entry $3.70 Now $3.12 −15.68% settles Nov 17
  2. Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $3.57 to $3.12 Now $3.12 −12.61% ▼ −12.61% −10.91% vs SPY
  3. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $3.65 to $3.70 Now $3.12 −14.52% ▲ +1.37% +1.96% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $6.02 to $5.15 Now $3.12 −48.17% ▼ −14.45% −13.26% vs SPY
  5. Sep 21, 20268w ago SC 13D/A Bearish 7/10 Entry $6.02 to $5.15 Now $3.12 +48.17% ▲ +14.45% +13.26% vs SPY
  6. Sep 17, 20268w ago 144 Bearish 5/10 Entry $5.96 to $5.23 Now $3.12 +47.65% ▲ +12.25% +13.52% vs SPY
  7. Aug 10, 202614w ago 8-K Bearish 7/10 Entry $4.50 to $5.91 Now $3.12 +30.67% ▼ −31.33% −31.38% vs SPY
  8. Aug 6, 202614w ago 8-K Neutral 4/10 Viewing Entry $49.61 to $6.54 Now $3.12 −93.71% ▼ −86.82% −88.03% vs SPY
  9. Jul 9, 202618w ago Insider Cluster Neutral 4/10 Entry $45.29 to $45.29 Now $3.12 −93.11% · 0.00% +0.56% vs SPY
  10. Jul 9, 202618w ago Insider Cluster Bearish 5/10 Entry $45.29 to $45.29 Now $3.12 +93.11% · 0.00% −0.56% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 8h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026